Drug Profile


Alternative Names: ENERGI-F701

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Energenesis Biomedical
  • Class Skin disorder therapies
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia

Most Recent Events

  • 23 May 2018 Phase-II clinical trials in Alopecia in Taiwan (Topical) (NCT03351322)
  • 22 Nov 2017 Energenesis Biomedical and A2 Healthcare Taiwan Corporation plan a phase II trial for Alopecia (Topical) (NCT03351322)
  • 05 May 2016 Preclinical trials in Alopecia in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top